Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

What is your surveillance protocol for patients with common variable immunodeficiency receiving chronic IVIG therapy?

1
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · University Hospitals Cleveland Medical Center

No target IgG level per se- dose/interval should be titrated to clinical condition. In general, trough IgG on treatment should be higher than 500 mg/dL, or 500 mg/dL higher than baseline. Most patients will not be in optimal clinical condition (minimal fatigue, arthralgias, absence of chronic cough,...

Do you use MRD testing to guide maintenance therapy discontinuation in newly diagnosed non-high risk myeloma patients?

1
3 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

Major bias, incoming!The short answer is: yes, I use MRD to guide de-escalation and ultimately discontinuation in standard-risk patients with myeloma.Much of that sentiment comes from our work at the University of Chicago called MRD2STOP, where we allow patients to stop treatment if they are sustain...

Do you advise patients with a personal or family history of germ cell tumors to avoid endocrine disruptors such as marijuana/CBD, lavender oils, or tea tree oils?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Testicular Cancer Commons

No, I do not advise against MJH or other putative endocrine disruptors, other than cautioning against the general health effects of MJH. I assume the question was triggered by the concern regarding older reports of an association of MJH and the development of germ cell tumors. Several things: Our un...

How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Texas Oncology-The Woodlands

Until more data are available regarding the ocular safety and reviewed by the agency, I follow the recommendations. I feel there is a decent chance real-world experience may change this but officially I follow the recommendations as stated. Having said this, the testing recommended (“Conduct an opht...

In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

Absolutely. Abiraterone in this setting improves OS, MFS, and likely long-term remission/cure rates over 10+ years when combined with radiation and standard of care radiation. Suppose a patient cannot tolerate abiraterone or prednisone due to various comorbidities (e.g., diabetes, steroid intoleranc...

How do you approach patients with substance use disorders who require chemotherapy for their cancer?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Los Angeles VA Medical Center

This is, unfortunately, a common, challenging situation that requires addressing multiple facets of care.The first is having enough mental health support for the patient and having a non-judgmental approach. We're lucky to have embedded clinical psychologists in our oncology clinic at my institution...

How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?

2
3 Answers

Mednet Member
Mednet Member
Medical Oncology · The Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute

Vitiligo is quite often (not always) associated with good long-term clinical outcomes for melanoma patients treated with immune checkpoint therapy. It is an indication of the activity of the drug, as it is due to unleashing of the T-cells’ attack on the bystander melanocytes in addition to melanoma ...

How do you manage the chemotherapy portion of chemoradiation in a patient with stage IIIB (hydronephrosis) cervical cancer, on hemodialysis?

1
1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

I will make sure to discuss with the patient's nephrologist to see if there are any special considerations, but in general, it is safe to consider either carboplatin or cisplatin with appropriate dose medications while on hemodialysis. In managing these patients, I have found most nephrologists pref...

For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · NYU Langone Health

Leukopenia most often as lymphocytopenia, of course, is not unusual in lupus. Total WBC less than 4000 is an ACR classification criteria for the disease as is ALC less than 1500 on two occasions. SLICC disease classification requires ALC less than 1000. Total WBC < 3000 generates SLEDAI points. On t...

Is there any benefit to checking serum viscosity in patients with autoimmune disease and headaches/migraines to see if aspirin or clopidogrel may be beneficial?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama Birmingham

The serum viscosity test measures the time required for the serum to flow through a calibrated capillary tube under controlled pressure. Clinically significant elevations in viscosity (≥2.5 centipoise, normal range 1.4 - 1.8 cP) can cause symptoms and are most commonly seen in hyperviscosity syndrom...